Latest news: EXACT Therapeutics

04/09	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2026	CI
30/06	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
26/06	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE
26/06	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer	CI
18/06	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application	MT
29/05	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo	MT
10/04	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer	CI
27/01	Exact Therapeutics as Announces Positive Initial Safety Read-Out from the Phase 2 Enact Trial in Pancreatic Cancer	CI
24/11	Exact Therapeutics introduces new long-term incentive program	RE
26/09/25	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/09/25	Exact Therapeutics H1 operating loss widens to NOK 45.9 million	RE
12/08/25	EXACT Therapeutics AS to Present at the European Society for Medical Oncology Congress 2025	CI

More news

Press Releases: EXACT Therapeutics

04/09	EXACT Therapeutics publishes shareholder information regarding the delisting	AQ
03/09	EXACT Therapeutics first half 2026 interim report	AQ
31/08	EXACT Therapeutics AS - Issuance of share options	AQ
02/07	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
30/06	EXACT Therapeutics AS - Removal from trading	AQ

More press releases

Managers and Directors: EXACT Therapeutics

Manager	Title	Age	Since
Per Walday CEO	Chief Executive Officer	66	06/06/2022
Svein Kvåle COO	Chief Operating Officer	-	01/01/2012
John Edminson DFI	Director of Finance/CFO	-	01/10/2022

Director	Title	Age	Since
Masha Paule Nathalie Strømme CHM	Chairman	55	22/06/2018
Anders Wold CHM	Chairman	-	08/06/2022
Ann-Tove Kongsnes BRD	Director/Board Member	59	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT THERAPEUTICS	+1.28%	+9.72%	-64.09%	-95.49%	5.29M
LONZA GROUP AG	+0.56%	-3.38%	-1.83%	+8.00%	45.63B
REVOLUTION MEDICINES, INC.	-1.21%	-2.40%	+337.98%	+537.11%	43.96B
IQVIA HOLDINGS INC.	+1.71%	+4.14%	+45.16%	+27.51%	43.73B
BEONE MEDICINES AG	-1.77%	-1.12%	+4.59%	+73.49%	40.23B
CELLTRION, INC.	-0.73%	-4.72%	+8.55%	+37.89%	31.86B
ASCENDIS PHARMA A/S	-12.52%	-14.09%	-	-	17.4B
MEDPACE HOLDINGS, INC.	+3.39%	+3.87%	+23.63%	+119.20%	16.62B
EUROFINS SCIENTIFIC SE	+1.83%	+3.20%	+16.49%	+32.73%	14.46B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.16%	-2.56%	+79.70%	+31.60%	13.04B
Average	-0.76%	-0.87%	+50.02%	+85.78%	26.69B
Weighted average by Cap.	-0.72%	-2.09%	+75.65%	+129.08%

See all sector performances

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/09/26	NOK 0.7900	+1.28%	35,655
14/09/26	NOK 0.7800	+28.93%	199,578
11/09/26	NOK 0.6050	-15.97%	137,407
10/09/26	NOK 0.7200	+0.70%	36,998
09/09/26	NOK 0.7150	-0.69%	2,000

Real-time Oslo Bors

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Oslo Bors 12:45:00 16/09/26 am AEST			5-day change	1st Jan Change
0.7900 ^NOK	+1.28%		+9.72%	-42.75%

Market Cap	49.35M 5.28M 4.58M 4.33M 3.92M 7.35M 507M 7.41M 51.65M 19.87M 257M 19.85M 19.41M 820M	P/E 2024	-2.49x	P/E 2025	-1x
Enterprise Value	25.43M 2.72M 2.36M 2.23M 2.02M 3.79M 261M 3.82M 26.62M 10.24M 132M 10.23M 10M 423M	EV / Sales 2024	-	EV / Sales 2025	1,074,437,000x
Free-Float	60.85%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Oslo Bors	EXTX	Real-time
Deutsche Boerse AG	56F	Delayed

1 day	+1.28%
1 week	+9.72%
Current month	+2.60%
1 month	+12.06%
3 months	+1.28%
6 months	-69.85%
Current year	-42.75%

1 week	0.6	0.85
1 month	0.6	0.85
Current year	0.58	2.7
1 year	0.58	2.78
3 years	0.58	17.5
5 years	0.58	22
10 years	0.58	53.59

EXACT Therapeutics Stock

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Valuation: EXACT Therapeutics

Chart: EXACT Therapeutics

Latest news: EXACT Therapeutics

Press Releases: EXACT Therapeutics

Quotes and Performance

Price Extremes

Managers and Directors: EXACT Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/1/23	Anders Wold	Buy	Chairman	2,500	0.0083%
4/1/23	Svein Kvåle	Buy	Founder	2,500	0.0083%
4/1/23	John Edminson	Buy	Chief Financial Officer	2,500	0.0083%

	2024	2025
Net sales	-	0.06 0.01 0.01 0.01 0 0.01 0.61 0.01 0.06 0.02 0.31 0.02 0.02 0.98
Net income	-52.33M -5.6M -4.85M -4.59M -4.16M -7.8M -538M -7.86M -54.78M -21.08M -273M -21.05M -20.59M -869M	-86.97M -9.31M -8.07M -7.63M -6.91M -12.96M -893M -13.06M -91.04M -35.02M -453M -34.99M -34.21M -1.44B
Net Debt	-98.89M -10.59M -9.17M -8.67M -7.85M -14.74M -1.02B -14.85M -104M -39.83M -515M -39.78M -38.9M -1.64B	-23.91M -2.56M -2.22M -2.1M -1.9M -3.56M -246M -3.59M -25.03M -9.63M -125M -9.62M -9.41M -397M